Morgan Ebert, Managing Editor

A study finds postmenopausal women have higher rates of dry eye disease, emphasizing the need for routine screening in clinical practice.

Real-world data show fezolinetant improves vasomotor symptoms, sleep, and work productivity in postmenopausal women.

Starting estrogen therapy in perimenopause was associated with reduced risks of breast cancer, heart attack, and stroke, study shows.

A new study found that transdermal hormone therapy may lower anxiety and depression risk compared with oral therapy in postmenopausal women.

A Wake Forest study finds that provider specialty and training shape how women receive medication treatment for menopause symptoms.

Most perimenopausal and menopausal women report digestive symptoms, but few receive diagnosis or adequate care, new UK study finds.

Researchers highlight overlap between menopause and TBI symptoms, calling for hormone-informed tools in brain injury assessment.

Tebipenem HBr met primary endpoints in a phase 3 trial, showing oral efficacy comparable to IV carbapenem for complicated urinary tract infections.

A review presented at The Menopause Society 2025 highlights the links between menopause-related brain changes and cognitive function.

A large TriNetX analysis found hormone therapy use in postmenopausal women was linked to a higher incidence of autoimmune diseases.

The Menopause Society’s 2025 meeting heads to Orlando with sessions on longevity, hormones, cognition, and care innovation at midlife and beyond.

Supplemental molecular breast imaging more than doubled invasive cancer detection rates in women with dense breasts.

New SMFM guidance outlines key recommendations for diagnosing, counseling, and managing heart failure in pregnancy and postpartum.

On October 2, 2025, the FDA approved a generic version of mifepristone to be used in a regimen with misoprostol for abortion.

Take a quick look at everything you may have missed during the third quarter of 2025, including the latest FDA approvals, top stories, and exclusive interviews.

Take a quick look at everything you may have missed in September, including the latest FDA updates, top stories, and exclusive interviews.

Check out the top conferences happening in the fourth quarter of 2025.

Mothers with multiple adverse childhood experiences faced double the risk of preterm birth, highlighting intergenerational health effects.

A study of 1.2 million children found no causal link between prenatal opioid use and autism or ADHD.

A national poll finds most women underestimate diet’s role in reducing menopause symptoms, despite evidence for plant-based diets with soy.

The 2025 amendment updates diagnostic, treatment, and prevention strategies for recurrent urinary tract infections in women.

Universal EHR-based decision support eliminated racial disparities in adolescent chlamydia and gonorrhea testing in pediatric EDs.

An international review found rising maternal age, increasing complications, and ongoing disparities in maternity care across 3 nations.

Take a quick look at everything you may have missed in August, including the latest FDA updates, top stories, and exclusive interviews.

Vaginal estrogen tablets were not associated with increased risk of recurrent ischemic stroke in postmenopausal women with prior stroke.

Biennial HPV testing and higher vaccination rates could help South Korea eliminate cervical cancer up to a decade earlier than with current policy.

Epigenetic aging raises colorectal cancer risk in postmenopausal women, but higher fruit and vegetable intake may help offset this risk.

OTC oral contraceptives boost access, with more women starting effective birth control, especially uninsured and rural populations.

Hypertensive disorders in pregnancy affect fetal growth differently by sex, with males prioritizing growth and females adapting via placental development.

Counties with persistently low cervical cancer screening rates have nearly double the rates of late-stage diagnoses and mortality, study finds.